Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
US-9687533-B2 · Jun 27, 2017 · US
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
US10220080B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10220080-B2 |
| Application number | US-201715599183-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 18, 2017 |
| Priority date | May 14, 2010 |
| Publication date | Mar 5, 2019 |
| Grant date | Mar 5, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
First claim
Opening claim text (preview).
We claim: 1. A therapeutic composition for detecting or modulating a splice variant polypeptide, comprising a pharmaceutically-acceptable carrier and an antibody or antigen-binding fragment thereof that exhibits binding specificity for an isolated aminoacyl-tRNA synthetase (AARS) splice variant polypeptide of SEQ ID NO: 53 or an epitope comprising at least 5 amino acids selected from SEQ ID NO: 48, 50, 99, and 101, wherein the composition has a purity of at least about 90% on a protein basis and less than about 10 EU endotoxin/mg protein. 2. The therapeutic composition of claim 1 , wherein the antibody or antigen binding fragment thereof is a monoclonal antibody. 3. The therapeutic composition of claim 1 , wherein the antibody is a humanized antibody. 4. The therapeutic composition of claim 1 , wherein the antibody or antigen-binding fragment thereof is an Fv fragment or a single chain Fv (sFv) polypeptide. 5. The therapeutic composition of claim 1 , wherein the composition is a sterile, freeze-dried powder. 6. The therapeutic composition of claim 1 , wherein the composition is a sterile injectable solution. 7. The therapeutic composition of claim 1 , wherein the composition is buffered and comprises an isotonic agent. 8. The therapeutic composition of claim 1 , wherein the composition is suitable for intravenous, intramuscular, subcutaneous, or intraperitoneal administration. 9. The therapeutic composition of claim 1 , wherein the composition comprises a surfactant. 10. The therapeutic composition of claim 1 , wherein the composition has a purity of at least about 95% on a protein basis.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Immunomodulators · CPC title
Drugs for immunological or allergic disorders · CPC title
Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers · CPC title
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10220080B2 cover?
- Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
- Who is the assignee on this patent?
- Atyr Pharma Inc, Pangu Biopharma Ltd, Atyr Pharam Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K38/53. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).